The BIKEN Group is a Specialty Bio-Pharmaceutical Organization
specializing in Vaccines.
In 2017, the Research Foundation of Osaka University, BIKEN Foundation, and BIKEN Corporation started a new chapter known as the “BIKEN Group.”
We will combine our strengths and work for better public health both in Japan and the entire world.
Press Release & Update
VLPT Japan, Biken Foundation, Denka sign agreement to develop self-amplifying “replicon” RNA influenza vaccine
VLPT Japan, Biken Foundation sign MoU on potential business alliance eying 2023 conclusion of “replicon” RNA COVID-19 vaccine production, sales license agreement
Announcement of BIKEN Group’s new board members
Approval of “GOBIK Aqueous Suspension Syringes”, Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine
Marketing Authorization Application of Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine (BK1310/MT-2355)
Regarding the Incident of Vaccine Culture Fluid Leakage at Seto Office